ALNY Q1 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$494M+54.8% YoY

Gross Profit

$428M86.7% margin

Operating Income

-$43M-8.8% margin

Net Income

-$66M-13.3% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

-$82M

Free Cash Flow

-$94M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$4.0B

Stockholders' Equity

-$219M

Cash & Equivalents

$682M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$494M	$319M	+54.8%
Gross Profit	$428M	$264M	+62.0%
Operating Income	-$43M	-$150M	+71.0%
Net Income	-$66M	-$174M	+62.1%

Revenue Segments

Product

$365M74%

ONPATTRO

$69M14%

GIVLAARI

$58M12%

Geographic Segments

UNITED STATES

$130M66%

Europe

$45M23%

Non-US Or Europe

$21M11%